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Objectives: There have been a number of controversies about which treatment of 
neuromuscular electrical stimulation (NMES) is more beneficial for overactive bladder 
(OAB). An attempt to investigate the therapeutic effect of NMES with different pulse widths 
for OAB in elderly women has been made in this study. 
Material and methods: The postmenopausal elderly women without pelvic organ prolapse 
(POP) who received transvaginal NMES in Beijing Hospital from November 2020 to 
December 2020 were randomly divided into two groups (Group A and Group B). Patients 
from Group A accepted the treatment with NMES by pulse width of 300 µs and patients from 
Group B accepted the treatment with NMES by pulse width of 200 µs. Myoelectric potential 
of Type I and Type II muscle fibers at pelvic floor and overactive bladder symptom score 
(OABSS) were valued. 
Results: There were 46 patients eligible for the study and randomly divided into Group A and
Group B, 23 patients for each group. OABSS were significantly reduced in both groups after 
the treatment of NEMS. And OABSS in Group A (after treated by pulse width of 300 µs) 
were significantly decreased greater than those in Group B (after treated with pulse width of 
200 µs). Both Group A and Group B had no significant difference in the mean myoelectric po-
tential at pre-resting state when compared before and after the treatment of NEMS. Myoelec-
tric potential of Type muscle fiber and the maximum myoelectric potential of Type muscle Ⅰ Ⅱ
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fibers were significantly increased after the treatment of NEMS than before the treatment in 
the two groups, respectively. And myoelectric potential of Type muscle fiber and the maxiⅠ -
mum myoelectric potential of Type muscle fibers in group A (after treated with pulse width Ⅱ
of 300 µs) were increased significantly much higher than those in Group B (after treated with 
pulse width of 200 µs).
Conclusions: Comparing the indicators before and after the treatments of NMES, our study 
has preliminarily confirmed that NMES has its advantages in treating with OAB. And NMES 
by pulse width of 300µs were more effective in improving pelvic floor muscle strength than 
NMES by pulse width of 200µs.
Key words: neuromuscular electrical stimulation; overactive bladder; pelvic floor muscles; 
overactive bladder symptom score; myoelectric potential; pulse width
INTRODUCTION
According to the Definition of the International Continence Society (ICS), an overactive 
bladder (OAB) was recognized as a “symptom syndrome suggestive of lower urinary tract 
dysfunction.” It is specifically defined as “urgency, with or without urge incontinence, usually
with frequency and nocturia” [1]. In China, the prevalence of OAB was 6.0% (5.9% for the 
male and 6.0% for the female), among which a female more than 50 years old accounted for 
46.3% [2]. In the United States, the prevalence of OAB was 16.5% (16.0% for the male, 
16.9% for the female) and has a trend of increasing with the age growing among the female 
(from 2% to 19%), especially among those more than 44 years old [3]. In Europe, 
epidemiological data indicated that among women over 40 years old, the prevalence of OAB 
was 16.6% and has been increased with the age growing as well [4]. It can be concluded that 
postmenopausal women are at a great risk of OAB. Studies have shown that in healthy 
postmenopausal middle-aged and elderly women, the incidence of OAB was 15–37% [5], 
among which 20.5% needed clinical intervention [6, 7], exerting great psychological pressure 
on patients. The pathogenesis of OAB mainly includes non-neurogenic detrusor instability, 
overactive bladder, dysfunctions of urethra and pelvic floor muscles, abnormal hormone 
metabolisms and so on. In addition to screening tests, overactive bladder symptom score 
(OABSS) has been proved to be highly sensitive to the diagnosis of OAB [8]. Traditional 
treatments for OAB include bladder training, pelvic floor muscle training (PRMT), 
anticholinergic drug, sacral nerve stimulation (SNS) and surgery. RCT studies have identified 
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that bladder training [9], PRMT [10, 11] and drug therapy [10] could improve the symptoms 
of OAB. However, the side effects of drug therapy, such as constipation and dry mouth, has 
affected the medication adherence, with only 10–30% of the OAB population taking the 
medication as prescribed for at least one year [12]. SNS and surgery are invasive treatments, 
with limits in the clinical practice. As a noninvasive treatment，some studies [13–16] have 
found that neuromuscular electrical stimulation (NMES) could inhibit unstable muscle 
contractions and spastic musculature, regulate the hypoxic state of the muscles and strengthen
the pelvic floor muscle, to improve pelvic floor disorders，such as pelvic organ prolapsed 
(POP), urinary incontinence and sexual dysfunction. However, there have been a number of 
controversies about which treatment of NMES is more beneficial for OAB. 
Objectives
Our study is aiming to compare the therapeutic effect of NMES with different pulse 
width for OAB in elderly women, providing evidence for the treatments.
MATERIAL AND METHODS
Subjects
Postmenopausal women with OAB as chief complaint in Beijing Hospital from 
November 2020 to December 2020 were selected.
Inclusion criteria 
(1) More than 12 months from the last menstrual period; 
(2) Score of "urgent urination" on OABSS questionnaire of overactive bladder (OABSS) ≥ 2 
points, and total score ≥ 3 points. Patients both meet the above two criteria can be enrolled.
Exclusion criteria 
(1) Routine urine test suggested urinary tract infection or ultrasound suggested vesical 
calculus; 
(2) Pelvic organ prolapse quantification system (POP-Q) suggested the lowest extent in the 
vagina was ≥ 0 cm from the hymenal ring; 
(3) Patients had taken anticholinergic drugs or received behavioral therapy for OAB such as 
bladder training three months before the enrollment; 
(4) Patients with a pacemaker implanted; 
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(5) Patients in the acute stage of vaginal inflammation; 
(6) Patients with malignant tumors;
(7) Patients suffering from mental illness and unable to cooperate with treatments; 
(8) Transabdominal ultrasound indicated that the residual volume of urine in the bladder was 
> 50 mL; 
(9) Urination diary indicated that daily water intake was > 2000 mL in average; 
(10) Patients with nervous system diseases; 
(11) Patients with massive space-occupying lesions in pelvis cavity and abdominal cavity; 
(12) patients with a history of urological surgery. Patients meeting any of the exclusion 
criteria would be excluded.
Pre-treatment evaluation
The same doctor conducted the consultation, gynecological examination, POP-Q exami-
nation, and OABSS investigation for both groups. Two other operators were assigned to mea-
sure the pelvic floor myoelectric potential for the patients through the Pelvic Floor SEMG 
Analysis and Biological Feedback Training System (MID A2, Medlander, Nanjing City, 
China). Four symptoms addressing day-time frequency, night-time frequency, urgency, and 
urgency incontinence are scored in the Homma OABSS questionnaire (Appendix 1) [17]. The 
total score is the sum of the four parts.
Randomization
Eligible patients were randomly assigned based on balanced treatment assignments with 
a computerized randomization allocation sequence via using blocks of 46 opaque, sealed 
envelopes to include the information of the treatments of NMES with different pulse width 
(300 µs or 200 µs) and divided into two groups. Both the patients and the physician in the pre-
treatment evaluation were blind to the treatments. 
Treatments of NMES
Neuromuscular stimulation Therapy Systems (MID B6, Medlander, Nanjing City, China)
was applied in the treatment by two designated operators. With the patient in supine position, 
an electrode is placed into the vagina (the electrode is placed completely within the hymenal 
ring). Group A received the treatments with the frequency of 5Hz, pulse width of 300 µs, 
rampe time of 0 second and the duration of 30 minutes. Group B received the treatments with 
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the frequency of 5Hz, pulse width of 200 µs, rampe time of 0 second, the duration of 30 
minutes. The treatments were performed in both groups once every 2–3 days for a total of 10 
times. The therapeutic magnitude of the current is determined by the patients' feeling of strong
muscle contraction or tingling without pain. The maximum safe current was 100 mA.
Post-treatment evaluation
Two of the same operators in the pre-treatment evaluation were assigned to measure the 
pelvic floor myoelectric potential with the Pelvic Floor SEMG Analysis and Biological 
Feedback Training System (MID A2, Medlander, Nanjing City, China) and finish the OABSS 
questionnaire for the second time within two days after all the treatments performed for the 
patients.
Statistical analysis
The software of EpiData 3.1 was used to input research data and SPSS 32.0 was used for
statistical analysis. The quantitative variables within each group were described using means, 
medians and standard deviations. In addition, the Shapiro-Wilk normality test was applied. 
For variables with normal distribution in the two groups, Student's t test was used to compare 
between the groups; otherwise, the Mann-Whitney test was used. For paired data in the pre- 
and post- treatment with normal distribution, paired t-test was used; otherwise, Wilcoxon 
signed rank test was used. The qualitative variables were described with frequencies and 
percentages and analyzed with Chi-square test. All tests were two sided, and p-values < 0.05 
were considered statistically different. According to the principle of intent-to-treat analysis 




There were 46 patients eligible for the study and randomly divided into two groups, 23 
patients for each group. Group A received treatment of NMES by pulse width of 300 µs, and 
Group B received treatment of NMES by pulse width of 200 µs. respectively. A total of five 
patients (1 from Group A and 4 form Group B) did not complete all the treatments and 
withdrew from the study, among which three patients (1 from Group A and 2 from Group B) 
were not able to reach the outpatient department during the scheduled time, one patient (from 
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Group B) was hospitalized for lung infection, one patient (from Group B) had impaired 
glucose tolerance (IGT) during the treatments. Finally, 22 patients of Group A and 19 patients 
of Group B completed all the treatments. The five patients who withdrew from the study also 
finished post-treatment evaluation within the scheduled time. 
During the treatments of NMES, there were three patients (2 from Group A and 1 from 
Group B) suffered from slight abdominal pain, which disappeared spontaneously 1–3 days 
later; there was another one patient (from Group A) suffered from increased vaginal 
secretions, which was confirmed to have bacterial vaginosis later by laboratory tests and 
recovered after treated with oral metronidazole for one week. All four patients continued the 
original treatments after the symptoms disappeared. There were no other complaints from the 
patients.
According to the principle of ITT analysis, all the 46 patients were analyzed statistically, 
as shown in Figure 1.
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4 patients withdrew :
2 patients unable to reach the outpatient 
department during the scheduled time;
1 patient hospitalized for lung infection;
1 patient suffering from impaired glucose 
tolerance
3 patients with adverse reactions:
2 patients suffered from slight abdominal 
pain
1 patient suffered from increased vaginal 
secretions
1 patient withdrew:
unable to reach the outpatient 
department during the 
scheduled time
1 patient with adverse reactions:





1 patient finished the 
post-treatment 
evaluation







46 patients included in the 
statistical analysis because of the 
principle of ITT analysis
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Comparison of the baseline between Group A and Group B
As shown in Table 1, there was no significant difference in baseline between 
Group A and Group B, including age (U = 211.000, p = 0.237), BMI (t = 0.377, p = 
0.708), delivery times (U = 253.000, p = 0.713), cesarean section rate, and forceps 
delivery rate (U = 1.095, p = 0.295).
Table 1. Comparison of the baseline between Group A and Group B
Baseline Group A Group B U p
No. 23 23 – –
Age [years old] 57 (55.58) 56 (54.58) 211.000& 0.237
BMI [kg/m2] 24.34 ± 2.46 24.08 ± 2.37 0.377* 0.708
Delivery times 1 (1.1) 1 (1.1) 253.000& 0.713
Cesarean section rate [%] 7/23 7/23 – –
Forceps delivery rate [%] 3/23 1/23 1.095# 0.295
BMI — body mass index; *referred to student’s t test; #referred to chi-square test; 
&referred to Mann-Whitney U
Comparison of the indicators before and after the treatments of NMES by pulse 
width of 300 µs in Group A
As shown in Table 2, in Group A, OABSS (Z = –4.221, p < 0.001) and mean 
myoelectric potential at pre-resting state (Z = –4.198, p < 0.001) were significantly 
decreased after the treatments of NMES by pulse width of 300 µs in comparison with 
those before the treatments. The myoelectric potential of Type muscle fibers (Z = Ⅰ –
3.407, p = 0.001) and the maximum myoelectric potential of Type muscle fibers (t = Ⅱ
-4.577, p < 0.001) were significantly increased after the treatments of NMES in 
comparison with those before the treatments. 
Table 2. Comparison of the indicators before and after the treatments of 
neuromuscular electrical stimulation by pulse width of 300 µs in Group A
Indicators Pre-treatment Post-treatment Z p
OABSS 8 (7, 9) 2 (1, 4) –4.221& < 0.001
mean myoelectric potential 
at pre-resting state [μv]
4.45 (2.06, 6.88) 1.10 (0.80, 2.00) –4.198& < 0.001
Mean myoelectric potential 









tential of Type muscle Ⅱ
fibers (fast-twitch) [μv]
25.48 ± 13.81 34.25 ± 13.00 –4.577* < 0.001
OABSS — overactive bladder symptom score; *referred to paired t test; 
&referred to Wilcoxon rank-sum test
Comparison of the indicators before and after the treatments of neuromuscular 
electrical stimulation by pulse width of 200 µs in Group B
As shown in Table 3, in Group B, OABSS (Z = –4.217, p < 0.001) and mean 
myoelectric potential at pre-resting state (Z = –4.198, p < 0.001) were significantly 
decreased after the treatments of NMES by pulse width of 200 µs in comparison with 
those before the treatments. However, mean myoelectric potential of Type muscle Ⅰ
fibers (Z = –0.396, p = 0.692) and the maximum myoelectric potential of 
Type muscle fibers (t = 0.107, Ⅱ p = 0.915) were both not significantly different after 
the treatments of NMES in comparison with those before the treatments. 
Table 3. Comparison of the indicators before and after the treatments of 
neuromuscular electrical stimulation in Group B
Indicators Pre-treatment Post-treatment Z p
OABSS 9 (6, 10) 5 (2, 6) –4.217& < 0.001
mean myoelectric potential
at pre-resting state [μv]
3.03 (2.18, 5.12) 1.57 (1.20, 2.29) –4.198& < 0.001
Mean myoelectric potential








tential of Type muscle Ⅱ
fibers (fast-twitch) [μv]
25.99 ± 10.07 25.91 ± 10.84 0.107* 0.915
OABSS — overactive bladder symptom score; *referred to paired t test; 
&referred to Wilcoxon rank-sum test
Comparison of the differences of the indicators before and after the treatments 
of NMES with different pulse widths between Group A and Group B 
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As shown in Table 4, before the treatments of NMES, OABSS (U = 246.500, p =
0.689), mean myoelectric potential at pre-resting state (U = 232.500, p = 0.482), mean
myoelectric potential of Type  muscle fibers (U = 255.000, Ⅰ p = 0.835) and the 
maximum myoelectric potential of Type  muscle fiber (t = Ⅱ –0.143, p = 0.887) had no
significant difference between Group A and Group B.
After the treatments of NMES, OABSS (U = 142.000, p = 0.006) in Group A 
(treated by pulse width of 300 µs) was significantly lower than that in Group B 
(treated by pulse width of 200 µs). Mean myoelectric potential at pre-resting state (U 
= 190.000, p = 0.101) was not significantly different between the two groups after the 
treatments of NMES with different pulse widths. Mean myoelectric potential of Type 
 muscle fibers (U = 64.000, Ⅰ p < 0.001) and the maximum myoelectric potential of 
Type  muscle fibers (t = 2.363, Ⅱ p = 0.023) in Group A (treated by pulse width of 300 
µs) were both significantly higher than those in Group B (treated by pulse width of 
200 µs), as shown in Table 5.
We also compare the differences of the indicators before and after the treatments 
of NMES in Group A (treated by pulse width of 300 µs) and Group B (treated by 
pulse width of 200 µs). As shown in Table 6, the difference of OABSS before and af-
ter the treatments of NMES in Group A were significantly greater than that in Group 
B (t = –3.506, p = 0.001). The differences of mean myoelectric potential at pre-resting
state before and after the treatments of NMES were not significantly different be-
tween the two groups (U = 184.000, p = 0.077). The differences of myoelectric poten-
tial of Type  muscle fibers (U = 80.000, Ⅰ p < 0.001) and the maximum myoelectric 
potential of Type  muscle fibers (t = 5.256, Ⅱ p < 0.001) were both significantly greater
in Group A than those in Group B. 
Table 4. Comparison of the differences of the indicators before the treatments of 
neuromuscular electrical stimulation with different pulse widths between Group 
A and Group B
Indicators Group A Group B U P
OABSS 8 (7, 9) 9 (6, 10) 246.500& 0.689
mean myoelectric poten-
tial at pre-resting state 
[μv]
4.45 (2.06, 6.88) 3.03 (2.18, 5.12) 232.500& 0.482
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Mean myoelectric po-







potential of Type  musⅡ -
cle fibers (fast-twitch) 
[μv]
25.48 ± 13.81 25.99 ± 10.07 –0.143* 0.887
OABSS — overactive bladder symptom score; *referred to student’s t test; &referred 
to Mann-Whitney U
Table 5. Comparison of the differences of the indicators after the treatments of 
neuromuscular electrical stimulation with different pulse widths between Group 
A and Group B
Indicators Group A Group B U P
OABSS 2 (1, 4) 5 (2, 6) 142.000& 0.006
mean myoelectric potential 
at pre-resting state [μv]
1.10 (0.80, 2.00) 1.57 (1.20, 2.29) 190.000& 0.101
Mean myoelectric potential 









tential of Type  muscle Ⅱ
fibers (fast-twitch) [μv]
34.25 ± 13.00 25.91 ± 10.84 2.363* 0.023
OABSS — overactive bladder symptom score; *referred to student’s t test; &referred 
to Mann-Whitney U
Table 6. Comparison of the differences of the indicators before and after the 
treatments of neuromuscular electrical stimulation with different pulse widths 
between Group A and Group B
Indicators Group A Group B U p
OABSS –5.61 ± 1.95 –3.83 ± 1.47 –3.506* 0.001
mean myoelectric poten-








tial of Type  muscle Ⅰ






potential of Type  musⅡ -
cle fibers (fast-twitch) 
[μv]
9.71 ± 8.13 –0.08 ± 3.73 5.256* < 0.001
OABSS — overactive bladder symptom score; *referred to student’s t test; &referred 
to Mann-Whitney U
DISCUSSION
In the treatments of NMES, mean myoelectric potential at pre-resting state is 
positively correlated with the spasm of pelvic floor muscles, which has been con-
firmed to be the main cause of OAB [18]. Mean myoelectric potential of Type  musⅠ -
cle fibers and the maximum myoelectric potential of Type  muscle fibersⅡ , as the indi-
cators for the functions of the pelvic floor muscles, are both associated with urinary 
continence. Our study found that after being treated with NEMS by different pulse 
widths, both Group A (treated by pulse width of 300 µs) and Group B (treated by 
pulse width of 200 µs) had no significant difference in the mean myoelectric potential 
at pre-resting state, indicating that the treatments may have been no help in reducing 
the high tension of pelvic floor muscles. However, after being treated with NEMS by 
different pulse widths, myoelectric potential of Type  muscle fiberⅠ  and the maximum 
myoelectric potential of Type  muscle fibers were significantly increased than prior Ⅱ
to the treatment of NEMS in the two groups, respectively. And when compared the 
two groups having been treated with NEMS by different pulse widths, we found that 
myoelectric potential of Type  muscle fiber and the maximum myoelectric potential Ⅰ
of Type  muscle fibers in group A (treated by pulse width of 300 µs) were Ⅱ increased 
much higher than those in Group B (treated by pulse width of 200 µs). In addition, af-
ter the treatments of NMES by different pulse widths, OABSS were significantly re-
duced than before the treatment of NEMS in the two groups, respectively. And when 
compared the two groups treated with NEMS by different pulse widths, we found that
OABSS in group A (treated by pulse width of 300 µs) were decreased greater than 
those in Group B (treated by pulse width of 200 µs), indicating that the patients 
treated with NEMS by pulse width of 300 µs can improve the ability of urinary conti-
nence more effectively than patients treated with NEMS by pulse width of 200 µs. 
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Mechanisms of NMES for OAB
OAB is composed by the symptoms of frequent, urgent urination or urge inconti-
nence. Clinically, the etiology of OAB still keep unclear. According to the different 
pathogenesis, OAB can be divided into three categories: detrusor instability, detrusor 
hyperreflexia, and bladder hypersensitivity, i.e., the initial urine volume of the bladder
is less than 100 ml. The pathophysiological changes of OAB include occulted neuro-
genic bladder, undetected bladder outlet obstruction, urethral-related bladder obstruc-
tion, senile urinary epithelial dysfunction, chronic bladder ischemia, chronic bladder 
inflammation, central sensitization, and autonomic nerve dysfunction [19]. Low-fre-
quency electrical stimulation can increase blood supply of the muscle and its nerve, 
eliminate fatigue and hypoxia, inhibit excessive nerve sensitivity and reduce muscle 
hypertonic, so as to improve the symptoms of OAB. In a study of percutaneous elec-
trical stimulation in the anesthetized cats, 30 minutes of electrical stimulation pro-
duced long-term post-stimulatory inhibition, and bladder volume increased signifi-
cantly after treatment, reaching up to 140.5 ± 7.6% of the control. In the post-treat-
ment period, the time of bladder contraction was significantly prolonged, reaching up 
to 200% of the control [20].
Analysis for the therapeutic differences with NMES treatments
With low-frequency pulse current, NMES is able to make alpha-motor unit action
potentials (MUAP) in peripheral nerves, which rapidly reach the threshold. As a re-
sult, more muscle fibers can participate in the contraction, strengthen the muscle and 
restore the body's motor function [21]. NMES may improve muscle strength by acting
on microrNa-486 /PTEN/FoxO1 pathway and reducing muscle atrophy furtherly [22].
Other studies have shown that NMES could effectively increase the thickness of 
skeletal muscle [23] and increase muscle strength [24]. Type  muscle fibers accounts Ⅰ
for 68–90% of deep pelvic floor muscles, characterized by tetanic contraction and rel-
ative indefatigability, whose role is to maintain the basic functions at resting state of 
the pelvic floor. Type II muscle fibers are mainly distributed in superficial pelvic floor
muscles, characterized by periodic and quick contraction and fatigability, whose role 
is to cope with the exploding force from the outside. Regarding the electrophysiologi-
cal characteristics of different types of muscle fibers, the pulse width of electrical 
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stimulation should be different too.
In this study, the treatment of NMES for Group A had an analgesic effect with 
the release of immunoreactive β-endorphin into the cerebrospinal fluid (1–10 Hz, 300 
µs, R = 0, the maximum current) [25], closer to electrophysiological characteristics of
Type  muscle fibers, which could relax the muscles from the spasm, improve blood Ⅰ
supply of the muscle and its nerve, and had analgesia effect. Apart from improving the
pelvic floor muscle strength, its main advantage lied in the therapeutic effect for urge 
incontinence with effectively reducing OABSS [13]. On the other hand, the treatment 
of NMES for Group B was a kind of analgesic treatment as well, but it was closer to 
electrophysiological characteristics of Type  muscle fibers with lower pulse width Ⅱ
[26]. In conclusion, Type muscle fibers have been playing a more important role in Ⅰ
maintaining the stability of pelvic floor functions.
In this study, it was found that the patients having been treated with NEMS by 
pulse width of 300 µs had more advantages than those patients having been treated 
with NEMS by pulse width of 200 µs in reducing OABSS and increasing myoelectric 
potential of pelvic floor muscle fibers. The mechanism may be that 300µs was more 
suitable for OAB patients with long-term high tension, spasm and ischemia of pelvic 
floor muscle fibers. Therefore, the treatments of NMES should be determined accord-
ing to the individual situation of the pelvic floor muscle fibers.
OABSS in China 
OABSS has been recommended by ICS for evaluating the symptoms of OAB. 
OABSS was reported by Homma for the first time in 2006 in Japan. Nowadays, it has 
been adopted in many foreign clinical researches [17, 27] and validated in China as 
well [28]. It is a self-report questionnaire, creating a single score for all the symptoms 
— OAB symptom score (OABSS), to quantify the OAB symptoms and evaluate its 
severity. In this study, after the treatments of NMES, OABSS in Group A and Group 
B were both significantly reduced, indicating that NEMS may be effective for OAB.
Comparison of different treatments for OAB 
The treatments for OAB in clinical practice mainly include behavior therapy 
(lifestyle changes, PFMT, biological feedback, etc.), drug therapy (Anticholinergic 
drugs, beta-3 adrenal agonists, estrogen, etc.) [29], sacral neuromodulation, et al. 
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However, these treatments have been existed with insurmountable limitations in clini-
cal application currently [24].
As the first-line treatment, behavior therapy could effectively improve the adher-
ence of the OAB patients. It is usually recommended to use before or with the drugs. 
Lifestyle changes, such as reasonable and effective liquid management, avoiding caf-
feine and soft drinks, reducing fluid intake before sleep, maintaining defecate unob-
structed, keeping a healthy weight and stopping smoking, can all improve the symp-
toms of OAB [30].
Drug therapy is the second-line treatment recommended by ICS. M cholinergic 
receptor blockers, by competitive inhibiting the acetylcholine in the smooth muscle of
bladder and postganglionic cholinergic receptor binding sites, has been used in clini-
cal practice for many years with its effectiveness widely confirmed. Unfortunately, 
about 80% of the patients had adverse effects of dry mouth. Up to 83% of the patients 
have stopped using the drug because of intolerance [31]. At present, the most widely 
studied beta-3 adrenergic agonists have been Mirabelone and Sorabelone. However, 
drug treatments of OAB cannot increase pelvic floor muscle strength, leaving limita-
tions in treating comprehensive urinary incontinence or pelvic floor dysfunctions 
combined with the weakened pelvic floor muscle strength.
Sacral nerve stimulation (SNS) is a third-line treatment recommended by ICS. It 
implants an electrode in the S3 sacral foramen, which is connected to an internal pulse
generator under the skin. The internal pulse generator emits pulses to release electric 
energy from the electrode, thereby stimulating the sacral and pudendal nerves, inhibit-
ing the detrusor contraction and relieving the patient's symptoms. However, due to its 
high cost and invasion, it is only applicable to patients with severe emergent inconti-
nence who cannot tolerate non-invasive treatments [32].
In the 1860s, Cadwell et al., began to study transvaginal electrical stimulation 
[33]. Subsequently, it has been proven to achieve therapeutic effects by stimulating 
the perineal nerve at frequencies below 12 Hz, to inhibit the detrusor muscle, regulate 
its involuntary contraction and reduce urination times [34]. Electrical stimulation has 
also been working in a passive way to help OAB patients be aware of their perineal 
(pelvic floor) muscle contractions, which may in turn help suppress involuntary detru-
sor contractions [35]. The advantage of NMES in clinical application lies in non-inva-
sion and definite effectiveness. However, the OAB patients still have difficulty com-
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plying with the schedule of the outpatient department. Portable electrical stimulation 
devices that can be used at home may become popular in the future.
Limitations 
In this study, the two groups of patients were not double-blind to the treatment. 
Fortunately, BMI, age, delivery times, OABSS and pelvic floor muscle strength be-
tween the two groups were not significantly different before the treatments, making 
the results of post treatment valuable. In further studies, randomized, double-blind, 
controlled trials should be designed to validate the therapeutic effectiveness of differ-
ent treatments of NMES, and to further explore whether it’s short-term or long-term 
effective.
CONCLUSIONS 
In conclusion, OAB is a common disease that seriously affects the life quality of 
postmenopausal elderly women. At present, it has been a hot issue in clinical practice 
to effectively improve OAB symptoms individually and comprehensively and im-
prove the pelvic floor functions for the patients at the same time. Comparing the indi-
cators before and after the treatments of NMES, our study has preliminarily con-
firmed that NMES has its advantages in treating with OAB, to improve the life quality
of the patients.
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Appendix 1. Overactive bladder symptom score (OABSS)
Item Symptom frequency/times Standard-
ized score
Score
1. day frequency How many times 
of urination from 
getting up in the 
morning to going 






How many times 





going to sleep at 
night to getting up
in the morning?
≥ 3 3
3. urgency Is there a sudden 





< 1 time per week 1
≥ 1 time per week 2
= 1 time per day 3
2–4 times per day 4
≥ 5 times per day 5
4. urgency inconti-
nence
Is there a sudden 




< 1 time per week 1
≥ 1 time per week 2
= 1 time per day 3
2–4 times per day 4
≥ 5 times per day 5
Total score:
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